Summary of medicine characteristics - GAVISCON ADVANCE SUSPENSION
1 NAME OF THE MEDICINAL PRODUCT
Gaviscon Advance Oral suspension.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
2 QUALITATIVE AND QUANTITATIVE COMPOSITION1 ml contains sodium alginate 100 mg and potassium hydrogen carbonate 20 mg.
Excipients (s) with known effect:
Methylparahydroxybenzoate (E218)
Propylparahydroxybenzoate (E216)
Calcium (80mg per 10ml)
For a full list of excipients, see Section 6.1.
3. PHARMACEUTICAL FORM
Oral suspension
Off-white, viscous suspension.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Treatment of symptoms of gastro-oesophageal reflux such as acid regurgitation,
heartburn and indigestion (related to reflux), for example, following meals, or during pregnancy, or in patients with symptoms related to reflux oesophagitis.
4.2. Posology and method of administration
Posology
Adults and children 12 years and over: 5–10 ml after meals and at bedtime.
Children under 12 years: Should be given only on medical advice.
Duration of treatment:
If symptoms do not improve after seven days, the clinical situation should be reviewed
Special patient groups:
Elderly: No dose modification is required for this age group.
Hepatic Impairment: No modifications necessary.
Renal Insufficiency: Caution if highly restricted salt diet is necessary (see section 4.4).
Method of administration
For oral use.
Shake well before use. Check that the cap seal is unbroken before first taking the product.
4.3. Contraindications
This medicinal product is contraindicated in patients with known or suspected hypersensitivity to the active substances or to any of the excipients listed in section 6.1, including methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) (see section 4.4).
4.4 Special Warnings and Special Precautions for Use
If symptoms do not improve after seven days, the clinical situation should be reviewed
Each 10 ml contains 200 mg (2.0 mmol) of calcium carbonate. Care needs to be taken in treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium containing renal calculi.
Contains methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216): May cause allergic reactions (possibly delayed).
For children below 12 years, please see section 4.2.
This medicinal product contains 106 mg (5.0 mmol) sodium per 10 ml dose, equivalent to 5.3% of the WHO recommended maximum daily intake for sodium, and 78 mg (2.0 mmol) of potassium.
The maximum daily dose of this product is equivalent to 21% of the WHO recommended maximum daily intake for sodium.
This product is considered high in sodium. This should be particularly taken into account for those on a low salt diet (e.g. in some cases of congestive heart failure and renal impairment) or when taking drugs which can increase plasma potassium levels.
4.5 Interaction with other Medicinal Products and other Forms of Interaction
Due to the presence of calcium and carbonates which act as an antacid, a timeinterval of 2 hours should be considered between Gaviscon intake and the administration of other medicinal products, especially tetracyclines, digoxin, fluoroquinolone, iron salts, thyroid hormones, ketoconazole, neuroleptics, penicilamine, beta-blockers (atenolol, metoprolol, propanolol), glucocorticoid, chloroquine, estramustine and diphosphonates. See also section 4.4.
4.6 Fertility, Pregnancy and lactation
Pregnancy:
Clinical studies in more than 500 pregnant women as well as a large amount of data from post-marketing experience indicate no malformative nor feto/neonatal toxicity of the active substances.
Gaviscon can be used during pregnancy if clinically needed.
Breastfeeding
No known effect on breastfed infants. Gaviscon can be used during breastfeeding.
Fertility:
No known effect on human fertility.
4.7 Effects on ability to drive and use machines
Gaviscon has no or negligible influence on the ability to drive or use machines.
4.8 Undesirable effects
Adverse reactions have been ranked under headings of frequency using the following convention: very common (1/10), common (1/100 and <1/10), uncommon (1/1000 and <1/100), rare (1/10,000 and <1/1000), very rare (<1/10,000) and not known (cannot be estimated from the available data).
| System Organ Class | Frequency | Adverse Event |
| Immune System Disorders | Very rare | Anaphylactic and anaphylactoid reactions. Hypersensitivity reactions such as urticaria. |
| Respiratory, Thoracic and Mediastinal Disorders | Very rare | Respiratory effects such as bronchospasm. |
Reporting of Suspected Adverse Reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the yellow card scheme www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
4.9 Overdose
Symptoms
Some abdominal discomfort may be experienced. The patient may notice abdominal distension.
Management
In the event of overdose, symptomatic treatment should be given.
5. PHARMACOLOGICAL PROPERTIES
5.1. Pharmacodynamic Properties
Pharmacotherapeutic classification: A02 BX, Other drugs for peptic ulcer and gastro-oesophageal reflux disease
On ingestion the suspension reacts with gastric acid to form a raft of alginic acid gel having a near-neutral pH and which floats on the stomach contents effectively (up to 4 hours) impeding gastro-oesophageal reflux. In severe cases the raft itself may be refluxed into the oesophagus in preference to the stomach contents and exert a demulcent effect.
5.2. Pharmacokinetic properties
The mode of action of this product is physical and does not depend on absorption into the systemic circulation.
5.3. Pre-clinical Safety Data
No preclinical findings of relevance to the prescriber have been reported.
6 PHARMACEUTICAL PARTICULARS
6.1. List of excipients
Calcium carbonate Carbomer 974P
Methyl parahydroxybenzoate (E218)
Propyl parahydroxybenzoate (E216)
Saccharin sodium
Fennel flavour
Sodium hydroxide (for pH adjustment)
Purified water
Ingredients of fennel flavour:
Fennel anethol
Benzyl alcohol
6.2. Incompatibilities
Not applicable.
6.3. Shelf-life
Shelf life: 2 years.
Shelf life after opening: 6 months.
6.4. Special Precautions for Storage
Do not refrigerate.
6.5. Nature and contents of container
Amber glass bottles with moulded polypropylene cap having a tamper evident strip and lined with an expanded polyethylene wad and containing 80, 100, 125, 140, 150, 180, 200, 250, 300, 400, 500, 560 or 600 ml suspension.
Or
Amber glass bottles with moulded polypropylene cap having a tamper evident strip and lined with an expanded polyethylene wad with either a measuring device (natural polypropylene) containing 5, 10, 15 and 20 ml graduations, or a measuring spoon (crystal polystyrene) containing 2.5 ml and 5 ml measure and containing 80, 100, 125, 140, 150, 180, 200, 250, 300, 400, 500, 560 or 600 ml suspension.
Not all pack sizes may be marketed. The carton and measuring device or spoon may not be made available in all markets/pack sizes.
6.6. Special precautions for disposal
Any unused product or waste material should be disposed of in accordance with local requirements.
7. MARKETING AUTHORISATION HOLDER
Reckitt Benckiser Healthcare (UK) Limited,
Dansom Lane,
Hull,
HU8 7DS,
United Kingdom
8. MARKETING AUTHORIZATION NUMBER(S)
8. MARKETING AUTHORIZATION NUMBER(S)PL 00063/0097
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
10/07/2018